UFPT Quote, Financials, Valuation and Earnings

Repligen has a net margin of 11.6% compared to UFP Technologies's net margin of 3.45%. UFP Technologies's return on equity of 19.38% beat Repligen's return on equity of -1.16%.

UFP Technologies has a consensus price target of $311.00, signalling upside risk potential of 36%. On the other hand Repligen has an analysts' consensus of $180.82 which suggests that it could grow by 51%. Given that Repligen has higher upside potential than UFP Technologies, analysts believe Repligen is more attractive than UFP Technologies.

UFP Technologies has a beta of 1.112, which suggesting that the stock is 11.208% more volatile than S&P 500. In comparison Repligen has a beta of 1.110, suggesting its more volatile than the S&P 500 by 10.976%.

UFP Technologies has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Repligen offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. UFP Technologies pays -- of its earnings as a dividend. Repligen pays out -- of its earnings as a dividend.

UFP Technologies quarterly revenues are $148.1M, which are smaller than Repligen quarterly revenues of $169.2M. UFP Technologies's net income of $17.2M is higher than Repligen's net income of $5.8M. Notably, UFP Technologies's price-to-earnings ratio is 27.99x while Repligen's PE ratio is 633.44x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for UFP Technologies is 3.25x versus 10.36x for Repligen. Usually stocks with elevated PS ratios are considered overvalued.

Tandem Diabetes Care has a net margin of 11.6% compared to UFP Technologies's net margin of -55.69%. UFP Technologies's return on equity of 19.38% beat Tandem Diabetes Care's return on equity of -81.14%.

UFP Technologies has a consensus price target of $311.00, signalling upside risk potential of 36%. On the other hand Tandem Diabetes Care has an analysts' consensus of $31.70 which suggests that it could grow by 101.27%. Given that Tandem Diabetes Care has higher upside potential than UFP Technologies, analysts believe Tandem Diabetes Care is more attractive than UFP Technologies.

UFP Technologies has a beta of 1.112, which suggesting that the stock is 11.208% more volatile than S&P 500. In comparison Tandem Diabetes Care has a beta of 1.478, suggesting its more volatile than the S&P 500 by 47.763%.

UFP Technologies has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Tandem Diabetes Care offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. UFP Technologies pays -- of its earnings as a dividend. Tandem Diabetes Care pays out -- of its earnings as a dividend.

UFP Technologies quarterly revenues are $148.1M, which are smaller than Tandem Diabetes Care quarterly revenues of $234.4M. UFP Technologies's net income of $17.2M is higher than Tandem Diabetes Care's net income of -$130.6M. Notably, UFP Technologies's price-to-earnings ratio is 27.99x while Tandem Diabetes Care's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for UFP Technologies is 3.25x versus 1.05x for Tandem Diabetes Care. Usually stocks with elevated PS ratios are considered overvalued.

VolitionRX has a net margin of 11.6% compared to UFP Technologies's net margin of -2201.34%. UFP Technologies's return on equity of 19.38% beat VolitionRX's return on equity of --.

UFP Technologies has a consensus price target of $311.00, signalling upside risk potential of 36%. On the other hand VolitionRX has an analysts' consensus of $2.94 which suggests that it could grow by 320%. Given that VolitionRX has higher upside potential than UFP Technologies, analysts believe VolitionRX is more attractive than UFP Technologies.

UFP Technologies has a beta of 1.112, which suggesting that the stock is 11.208% more volatile than S&P 500. In comparison VolitionRX has a beta of 1.198, suggesting its more volatile than the S&P 500 by 19.798%.

UFP Technologies has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. VolitionRX offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. UFP Technologies pays -- of its earnings as a dividend. VolitionRX pays out -- of its earnings as a dividend.

UFP Technologies quarterly revenues are $148.1M, which are larger than VolitionRX quarterly revenues of $246.4K. UFP Technologies's net income of $17.2M is higher than VolitionRX's net income of -$5.4M. Notably, UFP Technologies's price-to-earnings ratio is 27.99x while VolitionRX's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for UFP Technologies is 3.25x versus 48.25x for VolitionRX. Usually stocks with elevated PS ratios are considered overvalued.

Xtant Medical Holdings has a net margin of 11.6% compared to UFP Technologies's net margin of 0.18%. UFP Technologies's return on equity of 19.38% beat Xtant Medical Holdings's return on equity of -26.62%.

UFP Technologies has a consensus price target of $311.00, signalling upside risk potential of 36%. On the other hand Xtant Medical Holdings has an analysts' consensus of $1.75 which suggests that it could grow by 201.72%. Given that Xtant Medical Holdings has higher upside potential than UFP Technologies, analysts believe Xtant Medical Holdings is more attractive than UFP Technologies.

UFP Technologies has a beta of 1.112, which suggesting that the stock is 11.208% more volatile than S&P 500. In comparison Xtant Medical Holdings has a beta of -0.139, suggesting its less volatile than the S&P 500 by 113.918%.

UFP Technologies has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. UFP Technologies pays -- of its earnings as a dividend. Xtant Medical Holdings pays out -- of its earnings as a dividend.

UFP Technologies quarterly revenues are $148.1M, which are larger than Xtant Medical Holdings quarterly revenues of $32.9M. UFP Technologies's net income of $17.2M is higher than Xtant Medical Holdings's net income of $58K. Notably, UFP Technologies's price-to-earnings ratio is 27.99x while Xtant Medical Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for UFP Technologies is 3.25x versus 0.65x for Xtant Medical Holdings. Usually stocks with elevated PS ratios are considered overvalued.